Search

Your search keyword '"Soulayrol, S."' showing total 20 results
Start Over Author "Soulayrol, S."
20 results on '"Soulayrol, S."'

5. INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin

Author

Misra, Vijay P., Colosimo, Carlo, Charles, David, Chung, Tae Mo, Maisonobe, Pascal, Om, Savary, Abdulnayef, A., Adatepe, N. U., Araujo Leite, M. A., Badarny, S., Bajenaru, O., Bares, M., Bejjani, P., Bergmans, B., Bhidayasiri, R., Bozic, H., Cardoso Costa, F. E., Carlstrom, C., Castelnovo, G., Chang, M. H., Chang, Y. Y., Coletti-Moja, M., Delvaux, V., Dioszhegy, P., Dogu, O., Duzynski, W., Ehler, E., Espinosa Sierra, L., Fabbrini, G., Ferreira, J., Ferreira Valadas, A., Foresti, C., Girlanda, P., Goh, K. J., Graca Velon, A., Grill, S., Gurevitch, T., Hadidi, M., Hamimed, M. A., Hamri, A., Harrower, T., Hassin, S., Hedera, P., Hernandez, J. F. J. G., Hernandez Franco, J., Ho, B., Ho, S. L., Hughes, A., Ilic, T., Inshasi, J. S., Ip, C. W., Jamieson, S., Jamora, R. D. G., Jech, R., Jeon, B. S., Kaminska, A., Karpova, M., Khasanova, D., Kim, J. M., Kim, J. W., Kok, C. Y., Korenko, A., Korv, J., Koussa, S., Kovacs, T., Kreisler, A., Krystkowiak, P., Kumthornthip, W., Lin, C. H., Lundin, F., Lus, G., Magalhaes, M., Masmoudi, A. N., Mercelis, R., Misbahuddin, A., Moebius, C., Mohammadi, B., Nazem, B., Ng, K., Nurlu, G., Nyberg, J., Nyholm, D., Ochudlo, S., Otruba, P., Pfister, R., Pirtosek, Z., Pokhabov, D., Quinones Aguilar, S., Quinones Canales, G., Raghev, S., Rickmann, H., Romano, M., Rosales, R. L., Rubanovits, I., Santilli, V., Schoels, L., Simonetta-Moreau, M., Simu, M. A., Sohn, Y. H., Soulayrol, S., Supe, I., Svetel, M., Sycha, T., Tan, E. K., Timerbaeva, S., Tokcaer, A. B., Trosch, R., Tugnoli, V., Tumas, V., van der Linden, C., Vetra, A., Vial, C., Vidry, E., Williams, D., Wimalaratna, S., Yiannikas, C., Misra, Vijay P., Colosimo, Carlo, Charles, David, Chung, Tae Mo, Maisonobe, Pascal, Om, Savary, Abdulnayef, A., Adatepe, N. U., Araujo Leite, M. A., Badarny, S., Bajenaru, O., Bares, M., Bejjani, P., Bergmans, B., Bhidayasiri, R., Bozic, H., Cardoso Costa, F. E., Carlstrom, C., Castelnovo, G., Chang, M. H., Chang, Y. Y., Coletti-Moja, M., Delvaux, V., Dioszhegy, P., Dogu, O., Duzynski, W., Ehler, E., Espinosa Sierra, L., Fabbrini, G., Ferreira, J., Ferreira Valadas, A., Foresti, C., Girlanda, P., Goh, K. J., Graca Velon, A., Grill, S., Gurevitch, T., Hadidi, M., Hamimed, M. A., Hamri, A., Harrower, T., Hassin, S., Hedera, P., Hernandez, J. F. J. G., Hernandez Franco, J., Ho, B., Ho, S. L., Hughes, A., Ilic, T., Inshasi, J. S., Ip, C. W., Jamieson, S., Jamora, R. D. G., Jech, R., Jeon, B. S., Kaminska, A., Karpova, M., Khasanova, D., Kim, J. M., Kim, J. W., Kok, C. Y., Korenko, A., Korv, J., Koussa, S., Kovacs, T., Kreisler, A., Krystkowiak, P., Kumthornthip, W., Lin, C. H., Lundin, F., Lus, G., Magalhaes, M., Masmoudi, A. N., Mercelis, R., Misbahuddin, A., Moebius, C., Mohammadi, B., Nazem, B., Ng, K., Nurlu, G., Nyberg, J., Nyholm, D., Ochudlo, S., Otruba, P., Pfister, R., Pirtosek, Z., Pokhabov, D., Quinones Aguilar, S., Quinones Canales, G., Raghev, S., Rickmann, H., Romano, M., Rosales, R. L., Rubanovits, I., Santilli, V., Schoels, L., Simonetta-Moreau, M., Simu, M. A., Sohn, Y. H., Soulayrol, S., Supe, I., Svetel, M., Sycha, T., Tan, E. K., Timerbaeva, S., Tokcaer, A. B., Trosch, R., Tugnoli, V., Tumas, V., van der Linden, C., Vetra, A., Vial, C., Vidry, E., Williams, D., Wimalaratna, S., and Yiannikas, C.

Subjects
Male, Neurology, SATISFACTION, International Cooperation, Cohort Studies, 0302 clinical medicine, QUALITY-OF-LIFE, Botulinum toxin, Observational study, Tremor, Epidemiology, 030212 general & internal medicine, Cervical dystonia, Botulinum Toxins, Type A, Torticollis, Neuroradiology, BLEPHAROSPASM, education.field_of_study, Original Communication, INTEREST IN CD2 study group, Middle Aged, Treatment Outcome, Neuromuscular Agents, Female, Life Sciences & Biomedicine, medicine.drug, Adult, medicine.medical_specialty, Population, Clinical Neurology, DIAGNOSIS, 03 medical and health sciences, Patient satisfaction, Neurology (clinical), Internal medicine, medicine, Humans, education, Aged, Science & Technology, Neurology & Neurosurgery, Electromyography, GUIDANCE, business.industry, 1103 Clinical Sciences, medicine.disease, NEUROTOXIN, REGISTRY, UPDATE, Neurosciences & Neurology, 1109 Neurosciences, business, 030217 neurology & neurosurgery
Abstract

Background Longitudinal cohort studies provide important information about the clinical effectiveness of an intervention in the routine clinical setting, and are an opportunity to understand how a population presents for treatment and is managed. Methods INTEREST IN CD2 (NCT01753349) is a prospective, international, 3-year, longitudinal, observational study following the course of adult idiopathic cervical dystonia (CD) treated with botulinum neurotoxin type A (BoNT-A). The primary objective is to document long-term patient satisfaction with BoNT-A treatment. Here we report baseline data. Results This analysis includes 1036 subjects (67.4% of subjects were female; mean age was 54.7 years old; mean TWSTRS Total score was 31.7). BoNT-A injections were usually given in line with BoNT-A prescribing information. The most commonly injected muscles were splenius capitis (87.3%), sternocleidomastoid (82.6%), trapezius (64.3%), levator scapulae (40.9%) and semispinalis capitis (26.9%); 35.5% of subjects were injected using a guidance technique. Most subjects (87.8%) had been previously treated with BoNT-A (median interval between last pre-study injection and study baseline was 4 months); of these 84.8% reported satisfaction with BoNT-A treatment at peak effect during their previous treatment cycle and 51.5% remained satisfied at the end of the treatment. Analyses by geographical region revealed heterogeneity in the clinical characteristics and BoNT-A injection practice of CD subjects presenting for routine treatment. Conclusions These baseline analyses provide sizeable data regarding the epidemiology and clinical presentation of CD, and demonstrate an international heterogeneity of clinical practice. Future longitudinal analyses of the full 3-year study will explore how these factors impact treatment satisfaction. Electronic supplementary material The online version of this article (10.1007/s00415-017-8698-2) contains supplementary material, which is available to authorized users.

Published
2017

7. How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study

Author

Colosimo, C, Charles, D, Misra, VP, Maisonobe, P, Om, S, Abdulnayef, A, Adatepe, NU, Leite, AMA, Badarny, S, Bajenaru, O, Bares, M, Bejjani, P, Bergmans, B, Bhidayasiri, R, Bozic, H, Costa, CFE, Carlstrom, C, Castelnovo, G, Chang, MH, Chang, YY, Chung, TM, Coletti-Moja, M, Delvaux, V, Dioszhegy, P, Dogu, O, Duzynski, W, Ehler, E, Sierra, EL, Fabbrini, G, Ferreira, J, Valadas, FA, Foresti, C, Girlanda, P, Goh, KJ, Velon, GA, Grill, S, Gurevitch, T, Hadidi, M, Hamimed, MA, Hamri, A, Harrower, T, Hassin, S, Hedera, P, Hernandez, JFJG, Franco, HJ, Ho, B, Ho, SL, Hughes, A, Ilic, T, Inshasi, JS, Ip, CW, Jamieson, S, Jamora, RDG, Jech, R, Jeon, BS, Kaminska, A, Karpova, M, Khasanova, D, Kim, JM, Kim, JW, Kok, CY, Korenko, A, Korv, J, Koussa, S, Kovacs, T, Kreisler, A, Krystkowiak, P, Kumthornthip, W, Lin, CH, Lundin, F, Lus, G, Magalhaes, M, Masmoudi, AN, Mercelis, R, Misbahuddin, A, Moebius, C, Mohammadi, B, Nazem, B, Ng, K, Nurlu, G, Nyberg, J, Nyholm, D, Ochudlo, S, Otruba, P, Pfister, R, Pirtosek, Z, Pokhabov, D, Aguilar, QS, Canales, QG, Raghev, S, Rickmann, H, Romano, M, Rosales, RL, Rubanovits, I, Santilli, V, Schoels, L, Simonetta-Moreau, M, Ma, S, Sohn, YH, Soulayrol, S, Supe, I, Svetel, M, Sycha, T, Tan, EK, Timerbaeva, S, Tokcaer, AB, Trosch, R, Tugnoli, V, Tumas, V, Van der Linden, C, Vetra, A, Vial, C, Vidry, E, Williams, D, Wimalaratna, S, and Yiannikas, C

Subjects
0301 basic medicine, Male, Pediatrics, Neurology, SATISFACTION, Botulinum toxin, Cervical dystonia, Observational study, Satisfaction, Treatment, 0302 clinical medicine, QUALITY-OF-LIFE, Outcome Assessment, Health Care, Prospective Studies, Botulinum Toxins, Type A, Torticollis, Neuroradiology, BLEPHAROSPASM, INTEREST IN CD2 study group, Middle Aged, Neuromuscular Agents, Patient Satisfaction, SAFETY, Female, Life Sciences & Biomedicine, medicine.drug, Adult, medicine.medical_specialty, Adolescent, MEDLINE, Clinical Neurology, Treatment results, DIAGNOSIS, 03 medical and health sciences, Young Adult, medicine, Humans, Aged, Science & Technology, Neurology & Neurosurgery, business.industry, Correction, 1103 Clinical Sciences, medicine.disease, EFFICACY, 030104 developmental biology, Neurology (clinical), Neurosciences & Neurology, business, FOLLOW-UP, 1109 Neurosciences, 030217 neurology & neurosurgery, Botulinum toxin type
Abstract

Background Patients with cervical dystonia (CD) typically require regular injections of botulinum toxin to maintain symptomatic control. We aimed to document long-term patient satisfaction with CD symptom control in a large cohort of patients treated in routine practice. Methods This was a prospective, international, observational study (NCT01753349) following the course of adult CD treated with botulinum neurotoxin type A (BoNT-A) over 3 years. A comprehensive clinical assessment status was performed at each injection visit and subjects reported satisfaction in two ways: satisfaction with symptom control at peak effect and at the end of treatment cycle. Results Subject satisfaction remained relatively stable from the first to the last injection visit. At 3 years, 89.9% of subjects reported satisfaction with symptom control at peak effect and 55.6% reported satisfaction with symptom control at end of treatment cycle. By contrast, objective ratings of CD severity showed an overall reduction over 3 years. Mean ± SD Toronto Western Spasmodic Rating Scale (TWSTRS) Total scores (clinician assessed at end of treatment cycle) decreased from 31.59 ± 13.04 at baseline to 24.49 ± 12.43 at 3 years (mean ± SD reduction from baseline of − 6.97 ± 11.56 points). Tsui scale scores also showed gradual improvement; the percent of subjects with a tremor component score of 4 reduced from 12.4% at baseline to 8.1% at 3 years. Conclusions Despite objective clinical improvements over 3 years, subject satisfaction with symptom control remained relatively constant, indicating that factors other than symptom control also play a role in patient satisfaction.

Published
2019

10. Proprioceptive impairment and postural orientation control in Parkinson’s disease

Author

Vacherot, F., Vaugoyeau, Marianne, Mallau, S., Soulayrol, S., Assaiante, C., Azulay, J.P., Laboratoire de Neurosciences Cognitives [Marseille] (LNC), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), and Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, Parkinson's disease, Basal Ganglia, Weight-Bearing, 0302 clinical medicine, Center of pressure (terrestrial locomotion), Orthopedics and Sports Medicine, Postural Balance, ComputingMilieux_MISCELLANEOUS, media_common, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Neural Analyzers, 05 social sciences, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, General Medicine, Middle Aged, Illusions, Biomechanical Phenomena, medicine.anatomical_structure, Female, Psychology, medicine.medical_specialty, media_common.quotation_subject, Posture, Biophysics, Illusion, Experimental and Cognitive Psychology, Achilles Tendon, Vibration, 050105 experimental psychology, 03 medical and health sciences, Physical medicine and rehabilitation, Orientation, Physical Stimulation, Perception, medicine, Humans, 0501 psychology and cognitive sciences, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, Kinesthesis, Aged, Semicircular canal, Proprioception, [SCCO.NEUR]Cognitive science/Neuroscience, medicine.disease, Trunk, Sagittal plane, Accidental Falls, Sensory Deprivation, Neuroscience, 030217 neurology & neurosurgery
Abstract

Impairment of postural control is a common consequence of Parkinson's disease (PD). Increasing evidences demonstrate that the pathophysiology of postural disorders in PD includes deficits in proprioceptive processing and integration. However, the nature of these deficits has not been thoroughly examined. We propose to establish a link between proprioceptive impairments and postural deficits in PD using two different experimental approaches manipulating proprioceptive information. In the first one, the subjects stood on a platform that tilted slowly with oscillatory angular movements in the frontal or sagittal planes. The amplitude and frequency of these movements were kept below the semicircular canal perception threshold. Subjects were asked to maintain vertical body posture with and without vision. The orientations of body segments were analyzed. In the second one, the postural control was tested using the tendon-vibration method, which is known to generate illusory movement sensations and postural reactions. Vibrations were applied to ankle muscles. The subject's whole-body motor responses were analyzed from center of pressure displacements. In the first experiment, the parkinsonian patients (PP) were unable to maintain the vertical trunk orientation without vision. Their performances with vision improved, without fully reaching the level of control subjects (CS). In the second experiment, the postural reactions of the PP were similar to those of the CS at the beginning of the perturbation and increased drastically at the end of the perturbation's period as compared to those of CS and could induce fall. These results will bring new concepts to the sensorimotor postural control, to the physiopathology of posture, equilibrium and falls in PD and to the role of basal ganglia pathways in proprioception integration. Nevertheless, in order to assess precisely the role played by sensorimotor integration deficits in postural impairments in PD, further studies establishing the links between clinical features and abnormalities are now required.

Published
2011

16. Epilepsies and time to diagnosis

Author

Cachera, C., Baulac, M., Fagnani, F., Jallon, P., Leveau, J., Loiseau, P., Motte, J., Thomas, P., Vallee, L., Allaire, C., Autret, A., Baldy-Moulinier, M., Clanet, M., Dordain, G., Gastaut, J. L., Giroud, M., Josien, E., Marescaux, C., Masnou, P., Mauguiere, F., Parain, D., Perret, J., Revol, M., Rumbach, L., Tapie, P., Weber, M., Adam, C., Attal, N., Attane, F., Aubrun, P., Ayrivie, N., Badinand-Hubert, N., Bapst-Reiter, J., Barthez-Carpentier, M. A., Bartolomei, F., Bataillard, M., Bednarek, N., Belair, C., Benazet, M., Berges, S., Bergouignan, F. X., Bernard, C., Bernard-Bourzeix, L., Bertran, F., Bertrand, P., Beuriat, P., Billard, C., Bille-Turc, F., Billy, C., Biraben, A., Blanc, A., Boidein, F., Bouayed, N., Boudon, S., Bouillat, J., Boulloche, J., Bredin, A., Brocard, O., Brosset, P., Brunet-Bourgin, F., Cenraud, B., Chaigne, D., Chaix, Y., Chaunu, M. P., Chavot, D., Clavelou, P., Cohadon, S., Collombier, N., Contis, P. E., Convers, P., Couchot, J., Cournelle, M. A., Courtois, S., Croguennec, J. M., Cuisset, J. M., Cuvellier, J. C., D Anglejan, J., Damon, G., Danielli, A., Daubney, P., Bellescize, J., Lumley, L., Recondo, A., Swarte, M., Deffond, D., Delangre, T., Delisse, B., Derambure, P., Derambure, S., Desbordes, P., Desfrancois, F., Destee-Warot, M., Dien, J., Doremus, B., Dourneau-Lethiecq, M. C., Dubois, F., Duche, B., Ducrocq, X., Duhurt, J., Duprey, J., Durand, G., Dusser, A., Escaillas, J. P., Fanjaud, G., Felten, D., Fischer, C., Fontan, D., Formosa, F., Foulon, E., Furby, A., Gallet, S., Galmiche, J., Garde-Arthaud, P., Garrel, S., Gaultier, C., Gauthier, C., Gauthier-Morel, D., Genton, P., Geraud, G., Girard, J. P., Girard-Madoux, M., Gonnaud, P., Goulon-Goeau, C., Gros, S., Grosclaude, M., Gross, M., Gueguen, B., Guinot, H., Haenggeli, C. A., Hamon, J. B., Henlin, J. L., Hevin, B., Hinault, P., Homeyer, P., Hommet, C., Huart, E., Huc, P., Huttin, B., Inglesiakis, L., Isnard, J., Isnard, H., Jogeix, M., Juhel, C., Kahane, P., Kalafat, M., Keo-Kosal, P., Kreib, A. M., Kubler, C., Larrieu, E., Larrieu, J. L., Latinville, D., Le Gallou-Wittenberg, A., Lebas, F., Lebrun-Grandie, P., Leche, J., Legout, A., Legrand, S., Legroux, M., Lemaitre, J. F., Lestavel, P., Levasseur, M., Lienhard, C., Livet, M. O., Louiset, P., Lubeau, M., Lucas, B., Lucas-Daviaud, J., Maillard, S., Maillet-Vioud, M., Mancini, J., Mann, M., Marchal, C., Martini, L., Maupetit, J., Maynard, R., Menage, P., Menard, D., Metreau, R., Milor, M., Minot-Myhie, M. C., Moene, Y., Montagne, B., Montelescaut, M. E., Moreaud, O., Noelle, B., Olmi, X., Orbegozo, J., Ouvrard-Hernandez, A. M., Parsa, A., Pautrizel, B., Pedespan, J. M., Pernes, P., Perrouty, B., Petit, J., Peudenier, S., Picard, A. M., Pierrot-Deseilligny, C., Planque, E., Portha, C., Preux, P. M., Prud Homme, M., Raybaut-Guilhem, D., Rebaud, P., Regi, A., Regi, J. L., Reis, J., Rejou, F., Remy, C., Renard, J. F., Revenu, M., Revol, A., Rey, M., Richelme, C., Ricou, P., Rigal, J. P., Rogez, R., Rousselle, C., Rummens, C., Philippe Ryvlin, Sabouraud, P., Saikali, I., Saudeau, D., Savet, J. F., Schaeffer, J. L., Schaff, J. L., Schoenfelder, F., Schuermans, P., Senant, J., Setiey, A., Sevrin, C., Sivelle, G., Soisson, T., Soubielle, P., Soulages, X., Soulayrol, S., Tabaraud, F., Taillandier, P., Tannier, C., Tarel, V., Taussig, D., Thedrez, F., Tournier, C. L., Turc, J. D., Vanhulle, C., Vaunaize, J., Verier, A., Vernay, D., Visy, J. M., Vongsouthi, C., Vrigneaud, J., Waubant, E., Weichlein, A., Weill, O., Zai, L., Ziegler, F., Zix, C., Zelicourt, M., and Grp, Carole

19. [Treating writer's cramp: 14 years' experience with botulinum toxin].

Author

Somma-Mauvais H, Soulayrol S, Duvocelle A, Azulay JP, and Gastaut JL

Subjects
Adult, Botulinum Toxins, Type A administration & dosage, Combined Modality Therapy, Dystonic Disorders therapy, Female, Humans, Injections, Intramuscular, Male, Middle Aged, Neuromuscular Agents administration & dosage, Physical Therapy Modalities, Botulinum Toxins, Type A therapeutic use, Dystonic Disorders drug therapy, Neuromuscular Agents therapeutic use
Abstract

Introduction: Writer's cramp is a focal dystonia; treatment remains disappointing. We report our 14-year experience with a population of 119 patients aged between 18 and 85 years (average age 43 years)., Methods: Treatment was based on botulinum toxin injections (Dysport) and physiotherapy. Patients were reviewed every four to six months with clinical and video evaluation by three different observers and subjective analysis of the treatment efficiency by the patient (score of 1 to 3). The post-injection deficit, if present, was also quantified., Results: In the group treated with toxin and physiotherapy, cramps improved (score 2 and 3) in 61.6% of patients; a majority of patients (n=14) reported they were moderately satisfied (score 2). In the group treated with toxin alone, 37.9% of patients were improved (score 2 and 3) with a majority (n=18) very satisfied reporting normal writing (score 3). Age was not a predictor of therapeutic response. Good results were obtained with injections of the flexor carpi radialis followed by flexor digitorum profundus II and III and the flexor pollicis longus. Seventy-one per cent of injections caused moderate muscle weakness, minimally disabling compared to the benefit of injections. Twenty-seven patients were followed for more than two years and three patients, who had achieved score 3 with excellent response, were followed for 14 years with very efficient repeated injections. If the injections were not effective the first time, we re-assessed the situation and adjusted the injections; we considered that toxin treatment was unsuccessful after three injections without benefit., Conclusion: The choice treatment for writer's cramp remains well-targeted injections of botulinum toxin. Physiotherapy is useful when the toxin injections are ineffective in completely improving writing. This requires close cooperation between the injector, the physiotherapist and the patient.

Published
2010
Full Text
View/download PDF

20. [Treatments by local injections of botulinum toxin in neurology. Indications and results].

Author

Soulayrol S, Caperan A, Penot-Ragon C, Beaulieu JP, and Gastaut JL

Subjects
Aged, Botulinum Toxins administration & dosage, Female, Humans, Injections, Male, Middle Aged, Retrospective Studies, Botulinum Toxins therapeutic use, Nervous System Diseases drug therapy
Abstract

Local injections of botulinum toxin constitute the only truly effective treatment of certain abnormal movements and focal dystonias. The authors describe its indications and report on their personal experience. One hundred and seventeen patients were treated: 48 for blepharospasm, 46 for hemifacial spasm and 23 for spasmodic torticollis. The results were evaluated by means of a score taking into account the effectiveness of treatment, the duration of this effectiveness, the side-effects, if any, observed, and the course of the neurological disorder after several series of injections. The results were good or excellent in 91 percent of patients with hemifacial spasm and 79 percent of patients with blepharospasm. Spasmodic torticollis was much improved in 35 percent of the cases and less, but satisfactorily, improved in 48 percent. In this disease, the muscles which antagonize those responsible for the dystonia must absolutely be re-educated.

Published
1993

Catalog

Books, media, physical & digital resources
See catalog results